Bay 41-4109 (less active enantiomer);BAY41-4109 LESS ACTIVE ENANTIOMER; BAY-41-4109 LESS ACTIVE ENANTIOMER; BAYER 41-4109 LESS ACTIVE ENANTIOMER;Bayer 41-4109 less active enantiomer;methyl (4S)-4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoropyridin-2-yl)-6-methyl-1,4-dihydropyrimidine-5-carboxylate;5-Pyrimidinecarboxylic acid, 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-1,4-dihydro-6-methyl-, methyl ester, (4S)-;Bayer 41-4109 S-enantiomer
Bay 41-4109 (less active enantiomer) is the less active stereoisomer of BAY 41-4109, which is a potent inhibitor of human hepatitis B virus (HBV) with an IC₅₀ of 53 nM. BAY 41-4109 exerts its anti-HBV activity by targeting the viral capsid, accelerating and misdirecting capsid assembly in vitro, and stabilizing preformed capsids at a ratio of one inhibitor molecule per two dimers. It effectively inhibits HBV DNA release and reduces cytoplasmic HBcAg levels in HepG2.2.15 cells with IC₅₀ values of 32.6 nM and 132 nM, respectively, in a dose-dependent manner. In vivo, BAY 41-4109 dose-dependently reduces viral DNA levels in both liver and plasma with efficacy comparable to lamivudine (3TC), and decreases hepatitis B core antigen (HBcAg) in the livers of HBV-transgenic mice. Its antiviral mechanism is associated with and dependent on the inhibition of HBcAg. Pharmacokinetic studies show rapid absorption, moderate bioavailability (30% in mice, ~60% in rats and dogs), and dose-proportional plasma concentrations.